Income Statement
COLLEGIUM PHARMACEUTICAL, INC
COLL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
780.57 | 631.45 | 566.77 | 463.93 | 276.87 | 310.02 | 296.70 | 280.41 | - | - | - |
|
Cost of Revenue
|
317.31 | 254.11 | 240.60 | 254.45 | 126.25 | 130.18 | 193.66 | 165.68 | - | - | - |
|
Gross Profit
|
463.26 | 377.34 | 326.17 | 209.49 | 150.62 | 179.84 | 103.04 | 114.74 | - | - | - |
|
Operating Expenses
|
283.62 | 207.45 | 159.21 | 176.17 | 132.99 | 123.60 | 126.79 | 135.42 | 101.33 | 95.79 | 26.91 |
|
Research & Development
|
- | 0.00 | 0.00 | 3.98 | 9.45 | 9.77 | 10.34 | 8.66 | 8.57 | 14.95 | 7.98 |
|
Selling, General & Administrative
|
284.80 | 210.36 | 159.21 | 172.19 | 118.96 | 113.83 | 116.45 | 126.76 | 92.76 | 80.63 | 18.93 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
179.64 | 169.90 | 166.96 | 33.32 | 17.63 | 56.23 | -23.75 | -20.69 | -101.33 | -95.79 | -26.91 |
|
Non-Operating Income
|
87.02 | 71.33 | 91.23 | 62.17 | 21.00 | 28.65 | - | - | - | - | - |
|
Interest Income
|
- | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
58.38 | 59.82 | 83.34 | 63.21 | 21.01 | 28.88 | 0.91 | 20.13 | - | 0.09 | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | - | - | 0.58 | -0.09 | -0.35 |
|
Income Before Tax
|
92.62 | 98.57 | 75.73 | -28.85 | -3.37 | 27.58 | - | - | - | - | - |
|
Income Tax Expense
|
29.75 | 29.38 | 27.58 | -3.85 | -74.89 | 0.83 | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
62.87 | 69.19 | 48.16 | -25.00 | 71.52 | 26.75 | -22.72 | -39.13 | -74.87 | -94.18 | -27.26 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
179.64 | 169.90 | 166.96 | 33.32 | 17.63 | 56.23 | -23.02 | -19.61 | -100.73 | -95.14 | -26.91 |
|
Earnings Per Share (Basic)
|
1.98 | 2.14 | 1.43 | -0.74 | 2.05 | 0.78 | - | - | - | -3.88 | - |
|
Diluted EPS
|
1.73 | 1.86 | 1.29 | -0.74 | 1.86 | 0.76 | - | - | - | - | - |
|
Weighted Average Shares
|
31.71 | 32.27 | 33.74 | 33.83 | 34.94 | 34.41 | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
39.70 | 40.42 | 41.79 | 33.83 | 41.05 | 35.15 | - | - | - | - | - |
|
Comprehensive Income
|
63.13 | 69.23 | 48.17 | - | - | - | - | - | - | - | - |